June 29, 2018
Japan Tobacco and its pharma subsidiary Torii Pharmaceutical said on June 28 that they have decided to cease the development of the oral pruritus drug candidate serlopitant (development code: JTS-661). The two companies signed in 2016 a license agreement with...read more